Anti-LMO2 Rabbit Polyclonal Antibody for WB, ELISA - P25791

Core Product Specifications and Parameters

Biological Background: LMO2 Function and Localization

• LMO2 (Rhombotin-2) is a cysteine-rich LIM domain protein, also known as TTG-2 or RBTN2, encoded by the LMO2 gene in humans.
• It functions as a transcriptional co-regulator, partnering with TAL1/SCL to regulate red blood cell development and with LDB1 to maintain erythroid precursors in an immature state.
• LMO2 contains two LIM domains, which are zinc-binding motifs that mediate protein-protein interactions, and is subject to alternative splicing.
• Chromosomal rearrangements involving LMO2 are associated with T-cell acute lymphoblastic leukemia, highlighting its proto-oncogenic potential.
• The protein localizes to the nucleus, consistent with its role in transcriptional regulation.
• Key post-translational features include metal-binding (zinc) and the presence of tandem repeated LIM domains.
• High-resolution 3D structures have been determined, providing insights into its molecular interactions.

Experimental Guidance and Technical Tips

• The immunogen comprises a recombinant fusion protein covering amino acids 1-158 of human LMO2, expected to recognize the full-length native protein.
• For Western blot, a signal near 18 kDa is anticipated; consider using nuclear extracts from erythroid cell lines (e.g., K562) as positive control samples.
• In ELISA applications, pairing with a matched detection antibody may improve assay sensitivity; validate with recombinant LMO2 protein standards.
• Cross-reactivity with mouse and rat LMO2 is reported; verify performance in the model system of interest.

CamelBio: Your One-Stop Sourcing Bridge

As a dedicated one-stop sourcing partner for IVD manufacturers, CamelBio provides this anti-LMO2 antibody alongside related reagents for hematopoiesis and leukemia research. Our portfolio includes validated antibody pairs, optimized polyclonal and monoclonal antibodies, bulk ancillary reagents, and custom sourcing for rare targets, supporting every stage from concept to clinic.